Who are No low molecular weight heparin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): innohep®, Low dose dalteparin, Fragmin, Innohep (tinzaparin), Intermediate dose dalteparin, (Arm Closed) Dalteparin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/no-low-molecular-weight-heparin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

No low molecular weight heparin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

No low molecular weight heparin (No low molecular weight heparin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant. Area: Cardiovascular.

marketed Anticoagulant Factor Xa and thrombin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

No low molecular weight heparin (No low molecular weight heparin) — Beijing Anzhen Hospital. No low molecular weight heparin works by inhibiting Factor Xa and thrombin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
No low molecular weight heparin TARGET	No low molecular weight heparin	Beijing Anzhen Hospital	marketed	Anticoagulant	Factor Xa and thrombin
innohep®	innohep®	LEO Pharma	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (enhancer); Factor Xa and Thrombin (indirect targets)
Low dose dalteparin	Low dose dalteparin	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect); Factor Xa and Thrombin (downstream targets)
Fragmin	Dalteparin Sodium	Pfizer Inc.	marketed	Low molecular weight heparin (LMWH)	Factor Xa and thrombin
Innohep (tinzaparin)	Innohep (tinzaparin)	Ottawa Hospital Research Institute	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa and thrombin (via antithrombin III enhancement)
Intermediate dose dalteparin	Intermediate dose dalteparin	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect); Factor Xa and Thrombin (downstream targets)
(Arm Closed) Dalteparin	(Arm Closed) Dalteparin	University of Melbourne	phase 3	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect); Factor Xa and Thrombin (downstream targets)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant class)

Fresenius Kabi · 4 drugs in this class
University of Sao Paulo · 3 drugs in this class
Beijing Anzhen Hospital · 2 drugs in this class
San Filippo Neri General Hospital · 2 drugs in this class
Yong Seog Oh · 2 drugs in this class
CCRF Consulting Co., Ltd. · 1 drug in this class
Boston Scientific Corporation · 1 drug in this class
Beijing Suncadia Pharmaceuticals Co., Ltd · 1 drug in this class
Faculty Hospital Kralovske Vinohrady · 1 drug in this class
Deutsches Herzzentrum Muenchen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). No low molecular weight heparin — Competitive Intelligence Brief. https://druglandscape.com/ci/no-low-molecular-weight-heparin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab